High Neutrophil/Lymphocyte ratio (NLR), as a measure of enhanced inflammatory response, has been negatively associated with prognosis in patients with localized pancreatic ductal adenocarcinoma (PDA).

Formica, V., Morelli, C., Ferroni, P., Nardecchia, A., Tesauro, M., Pellicori, S., et al. (2016). Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. DISEASE MARKERS. SECTION A, CANCER BIOMARKERS, 17(3), 335-345 [10.3233/CBM-160645].

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin

FORMICA, VINCENZO;TESAURO, MANFREDI;Riondino, S;ROSELLI, MARIO
2016

Abstract

High Neutrophil/Lymphocyte ratio (NLR), as a measure of enhanced inflammatory response, has been negatively associated with prognosis in patients with localized pancreatic ductal adenocarcinoma (PDA).
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/06 - Oncologia Medica
Settore MED/04 - Patologia Generale
English
Con Impact Factor ISI
Neutrophil/lymphocyte ratio; gemcitabine; oxaliplatin; pancreatic ductal adenocarcinoma
Formica, V., Morelli, C., Ferroni, P., Nardecchia, A., Tesauro, M., Pellicori, S., et al. (2016). Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. DISEASE MARKERS. SECTION A, CANCER BIOMARKERS, 17(3), 335-345 [10.3233/CBM-160645].
Formica, V; Morelli, C; Ferroni, P; Nardecchia, A; Tesauro, M; Pellicori, S; Cereda, V; Russo, A; Riondino, S; Guadagni, F; Roselli, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/170813
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact